Titel: EuroTIDES: Oligonucleotides, siRNA and Peptides for the Manufacturing and Drug Development Industry
Termin:
10.11.2003
Veranstaltungsort:
Kurfürstendamm 27
10719 Berlin
Germany
Referenten: Keynote: Dr. Michael Gait (Senior Group Leader, Medical Research Council, UK)
This event will provide a comprehensive overview and an invaluable insight into the latest developments and news from the industry experts. With several antisense oligonucleotides close to NDA and more than 27 molecules in clinical trials, this field continues to grow at a phenomenal rate.
Topics to be covered at this event...
* Hear the latest findings and results on Genasense, will this be the next promising therapeutic for cancer?
* Has the potential of siRNA to provide new therapies been over-hyped?
* How are the problems of delivery and pharmaceutical development being addressed?
* The manufacture of oligonucleotides and siRNA as therapeutics and diagnostic products
* What are the next drugs that people have in development and why are they going to succeed where others have failed?
* The latest issues on large scale-up, purification, formulation, delivery, analytical characterisation and regulatory control for antisense and peptides
With rapid scientific advances, it is vital that you keep up to date with the latest information. Over the course of this conference you will hear from a panel of leading expert scientists who will tackle the issues surrounding antisense and peptide chemistry to decipher the hype from the reality.
Kontakt:
The Booking Department
Informa UK Limited
P.O. Box 406
West Byfleet KT 14 6NN
Great Britain
phone: +44 - (0)20 - 70 17 55 07
fax: +44 - (0)20 - 70 17 47 49
cust.serv@informa.com
http://www.ibc-lifesci.com/eurotides
Veranstalter: ibc Life Sciences (Part of Informa Life Science Group)
Wissenschaftliche Leitung: Dr Mark Douglas (Business Development Manager, Avecia Biotechnology, UK), Dr Troels Koch (Vice President Chemistry, Santaris Pharma A/S, Denmark), Dr James McArdle (Vice President, Analytical Development & Quality Control, Isis Pharmaceuticals Inc, USA), Professor John Rossi (Department of Molecular Biology, Beckman Research Institute, USA), Dr Yogesh S. Sanghvi (Executive Director, Development Chemistry, Isis Pharmaceuticals Inc, USA), Professor Cy Stein, Urology and Molecular Pharmacology, Albert Einstein College of Medicine, USA
Schlagworte: Biotechnologie